April 29 2022
Kati Stoermer,Executive Director of NRG Oncology since 2018, has announced that she will bestepping down from her role effective later in May. Having joined NRG Oncologyduring the final preparations for the renewal of the current NCTN grant, herfour plus years tenure has been marked by the successful implementation of thatgrant in addition to the successful renewals of the NRG Oncology NCORP ResearchBase and Biospecimen Banking Grants. In 2020, her leadership allowed theorganization to continue with little pause as the pandemic took hold. A majorfocus of her role in adapting to the pandemic-induced changes has been leadingthe revisioning and execution of the semiannual NRG Oncology meetings, with thenewest generation of hybrid NRG meetings planned for this summer. Otherhallmarks of her leadership have been the formation of a VeteransAffairs/Military Treatment Facilitate subcommittee to help those populationsengage in more NCI-funded clinical trials, admittedly a passion project for theUS Navy veteran.
“Kati’sdeparture will leave a hole in our organization, and we are sorry to see hergo,” noted Norman Wolmark, MD one of NRG’s Group Chairs.
NRG Oncology isnaming Sharon Hartson Stine as Interim Executive Director effective May 2,2022. “We are pleased that Sharon is able to assume the role of interimexecutive director while we evaluate the group’s current requirements in orderto ensure NRG’s success as we embark on this new chapter,” said Robert Mannel,MD, an NRG Group Chair. Hartson Stine currently serves as Senior Director, NRGOncology – Philadelphia West Operations Center and has been with theorganization since it formed in 2013 and for many years prior to that with theRTOG.
Stoermer willstay on to support the transition through May 20, 2022.